ACUMEN PHARMACEUTICALS INC (ABOS) Stock Balance Sheet
NASDAQ:ABOS - Nasdaq - US00509G2093 - Common Stock - Currency: USD
| MRQ (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 30.16M | 35.63M | 66.89M | 130.10M | 122.20M | |||
| Marketable Securities | 118.99M | 135.93M | 176.64M | 47.50M | 72.10M | |||
| Receivables | 376.00K | 398.00K | N/A | N/A | 0.00 | |||
| Other Current Assets | 5.42M | 6.35M | 3.09M | 2.70M | 4.40M | |||
| Total Current Assets | 154.95M | 178.31M | 246.62M | 180.30M | 198.70M | |||
| Non-Current Assets | ||||||||
| PPE Net | 373.00K | 339.00K | 503.00K | 300.00K | 0.00 | |||
| Investments And Advances | 48.80M | 59.97M | 62.55M | 15.80M | 31.60M | |||
| Other Non-Current Assets | 363.00K | 379.00K | 454.00K | 200.00K | 0.00 | |||
| Total Non-Current Assets | 49.53M | 60.69M | 63.51M | 16.30M | 31.60M | |||
| TOTAL ASSETS | 204.48M | 238.99M | 310.13M | 196.60M | 230.30M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | 0.00 | 756.00K | N/A | N/A | |||
| Accrued Expenses | 17.84M | 21.73M | 10.62M | 6.00M | 3.90M | |||
| Accounts Payable | 1.06M | 5.65M | 1.38M | 1.60M | 1.10M | |||
| Other Current Liabilities | 418.00K | 230.00K | 212.00K | 100.00K | 200.00K | |||
| Total Current Liabilities | 19.32M | 27.61M | 12.97M | 7.80M | 5.10M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 29.53M | 29.42M | 29.90M | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 114.00K | 150.00K | 284.00K | N/A | 0.00 | |||
| Total Non-Current Liabilities | 29.64M | 29.57M | 30.18M | 0.00 | 0.00 | |||
| TOTAL LIABILITIES | 48.96M | 57.18M | 43.15M | 7.80M | 5.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -353.92M | -325.13M | -222.80M | -170.40M | -127.60M | |||
| Additional Paid In Capital | 509.42M | 506.99M | 489.45M | 359.90M | 353.00M | |||
| Common Shares | 6.00K | 6.00K | 6.00K | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 15.00K | -48.00K | 312.00K | -800.00K | -200.00K | |||
| Shares Outstanding | 60.57M | 60.09M | 57.91M | 41.00M | 40.50M | |||
| Tangible Book Value per Share | 2.57 | 3.03 | 4.61 | 4.60 | 5.56 | |||
| Total Shareholders' Equity | 155.52M | 181.82M | 266.97M | 188.80M | 225.20M | |||
| TOTAL LIABILITIES AND EQUITY | 204.48M | 238.99M | 310.13M | 196.60M | 230.30M | |||
| Statistics | ||||||||
| Debt/Equity | 0.19 | 0.16 | 0.11 | N/A | N/A | |||
| Current Ratio | 8.02 | 6.46 | 19.01 | 23.12 | 38.96 | |||
| Return On Assets (ROA) | -57.08% | -42.68% | -16.77% | -21.80% | -43.69% | |||
| Return On Equity (ROE) | -75.05% | -56.10% | -19.48% | -22.70% | -44.68% | |||
All data in USD , ROIC based on taxRate of 0.21